Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo.
Identifieur interne : 003E53 ( Main/Exploration ); précédent : 003E52; suivant : 003E54Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo.
Auteurs : RBID : pubmed:9659224English descriptors
- KwdEn :
- Animals, Arthritis, Rheumatoid (immunology), Arthritis, Rheumatoid (metabolism), Arthritis, Rheumatoid (prevention & control), Cartilage, Articular (pathology), Cartilage, Articular (transplantation), Cell Adhesion Molecules (metabolism), Female, Humans, Immunohistochemistry, Interleukin-10 (therapeutic use), Interleukin-4 (therapeutic use), Leukocytes, Mononuclear (immunology), Male, Mice, Mice, SCID, Middle Aged, Synovial Membrane (immunology), Synovial Membrane (metabolism), Synovial Membrane (pathology), Synovial Membrane (transplantation), Transplantation, Heterologous.
- MESH :
- chemical , metabolism : Cell Adhesion Molecules.
- immunology : Arthritis, Rheumatoid, Leukocytes, Mononuclear, Synovial Membrane.
- metabolism : Arthritis, Rheumatoid, Synovial Membrane.
- pathology : Cartilage, Articular, Synovial Membrane.
- prevention & control : Arthritis, Rheumatoid.
- chemical , therapeutic use : Interleukin-10, Interleukin-4.
- transplantation : Cartilage, Articular, Synovial Membrane.
- Animals, Female, Humans, Immunohistochemistry, Male, Mice, Mice, SCID, Middle Aged, Transplantation, Heterologous.
Abstract
We used the severe combined immunodeficient (SCID) mouse model to assess the effect of interleukin-4 (IL-4) or IL-10 injection on cartilage degradation and mononuclear cell (MNC) recruitment to human rheumatoid synovium in vivo. Human rheumatoid synovium and cartilage from five rheumatoid arthritis patients, obtained after joint replacement surgery, were engrafted subcutaneously to 6-8-week-old SCID CB17 mice. Synovial tissues were injected with recombinant human IL-4 (rhIL-4, 100 ng; rhIL-10, 100 ng), both cytokines, or tumour necrosis factor-alpha (TNF-alpha) (1000 U), or phosphate-buffered saline twice a week for 4 weeks. The graft was removed and immunochemical analysis was carried out to assess intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin expression. Moreover, cartilage degradation was assessed through the quantification of the erosion surface on a computerized image of the engrafted cartilage at high power view. MNC recruitment in the synovial tissue was determined by labelling blood MNC with indium-111 before their intraperitoneal injection. The activity obtained in the region of the graft were determined with a gamma camera 72 hr postinjection. The results are expressed as a percentage of initial injected activity. After 4 weeks we observed a decrease of cartilage area in controls (77 +/- 8%), inhibited after injection of IL-4, IL-10, or both cytokines (90 +/- 3%, 89.1 +/- 4%, 89.2 +/- 5% respectively), and 57 +/- 17% after TNF-alpha injection. The % MNC activity in the graft decreased to 77 +/- 81% (NS), 9 +/- 4% (P < 0.003) and 19 +/- 6% (P < 0.007) compared with untreated synovial tissue after treatment with IL-4, IL-10, or both cytokines, respectively. Moreover, IL-10 but not IL-4 decreased the expression of ICAM-1 but not VCAM-1 or E-selectin by synovial cells. These results suggest that IL-10 and IL-4 could have chondroprotective properties, and that IL-10 but not IL-4 inhibits MNC traffic towards the synovial tissue efficiently.
PubMed: 9659224
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo.</title><author><name sortKey="Jorgensen, C" uniqKey="Jorgensen C">C Jorgensen</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Immuno-Rhumatologie, Lapeyronie Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Immuno-Rhumatologie, Lapeyronie Hospital, Montpellier</wicri:regionArea><placeName><region type="région">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Apparailly, F" uniqKey="Apparailly F">F Apparailly</name></author><author><name sortKey="Couret, I" uniqKey="Couret I">I Couret</name></author><author><name sortKey="Canovas, F" uniqKey="Canovas F">F Canovas</name></author><author><name sortKey="Jacquet, C" uniqKey="Jacquet C">C Jacquet</name></author><author><name sortKey="Sany, J" uniqKey="Sany J">J Sany</name></author></titleStmt><publicationStmt><date when="1998">1998</date><idno type="RBID">pubmed:9659224</idno><idno type="pmid">9659224</idno><idno type="wicri:Area/Main/Corpus">004095</idno><idno type="wicri:Area/Main/Curation">004095</idno><idno type="wicri:Area/Main/Exploration">003E53</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Arthritis, Rheumatoid (immunology)</term><term>Arthritis, Rheumatoid (metabolism)</term><term>Arthritis, Rheumatoid (prevention & control)</term><term>Cartilage, Articular (pathology)</term><term>Cartilage, Articular (transplantation)</term><term>Cell Adhesion Molecules (metabolism)</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>Interleukin-10 (therapeutic use)</term><term>Interleukin-4 (therapeutic use)</term><term>Leukocytes, Mononuclear (immunology)</term><term>Male</term><term>Mice</term><term>Mice, SCID</term><term>Middle Aged</term><term>Synovial Membrane (immunology)</term><term>Synovial Membrane (metabolism)</term><term>Synovial Membrane (pathology)</term><term>Synovial Membrane (transplantation)</term><term>Transplantation, Heterologous</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cell Adhesion Molecules</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Leukocytes, Mononuclear</term><term>Synovial Membrane</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Synovial Membrane</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Cartilage, Articular</term><term>Synovial Membrane</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Interleukin-10</term><term>Interleukin-4</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Cartilage, Articular</term><term>Synovial Membrane</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>Male</term><term>Mice</term><term>Mice, SCID</term><term>Middle Aged</term><term>Transplantation, Heterologous</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We used the severe combined immunodeficient (SCID) mouse model to assess the effect of interleukin-4 (IL-4) or IL-10 injection on cartilage degradation and mononuclear cell (MNC) recruitment to human rheumatoid synovium in vivo. Human rheumatoid synovium and cartilage from five rheumatoid arthritis patients, obtained after joint replacement surgery, were engrafted subcutaneously to 6-8-week-old SCID CB17 mice. Synovial tissues were injected with recombinant human IL-4 (rhIL-4, 100 ng; rhIL-10, 100 ng), both cytokines, or tumour necrosis factor-alpha (TNF-alpha) (1000 U), or phosphate-buffered saline twice a week for 4 weeks. The graft was removed and immunochemical analysis was carried out to assess intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin expression. Moreover, cartilage degradation was assessed through the quantification of the erosion surface on a computerized image of the engrafted cartilage at high power view. MNC recruitment in the synovial tissue was determined by labelling blood MNC with indium-111 before their intraperitoneal injection. The activity obtained in the region of the graft were determined with a gamma camera 72 hr postinjection. The results are expressed as a percentage of initial injected activity. After 4 weeks we observed a decrease of cartilage area in controls (77 +/- 8%), inhibited after injection of IL-4, IL-10, or both cytokines (90 +/- 3%, 89.1 +/- 4%, 89.2 +/- 5% respectively), and 57 +/- 17% after TNF-alpha injection. The % MNC activity in the graft decreased to 77 +/- 81% (NS), 9 +/- 4% (P < 0.003) and 19 +/- 6% (P < 0.007) compared with untreated synovial tissue after treatment with IL-4, IL-10, or both cytokines, respectively. Moreover, IL-10 but not IL-4 decreased the expression of ICAM-1 but not VCAM-1 or E-selectin by synovial cells. These results suggest that IL-10 and IL-4 could have chondroprotective properties, and that IL-10 but not IL-4 inhibits MNC traffic towards the synovial tissue efficiently.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9659224</PMID><DateCreated><Year>1998</Year><Month>07</Month><Day>27</Day></DateCreated><DateCompleted><Year>1998</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0019-2805</ISSN><JournalIssue CitedMedium="Print"><Volume>93</Volume><Issue>4</Issue><PubDate><Year>1998</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Immunology</Title><ISOAbbreviation>Immunology</ISOAbbreviation></Journal><ArticleTitle>Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo.</ArticleTitle><Pagination><MedlinePgn>518-23</MedlinePgn></Pagination><Abstract><AbstractText>We used the severe combined immunodeficient (SCID) mouse model to assess the effect of interleukin-4 (IL-4) or IL-10 injection on cartilage degradation and mononuclear cell (MNC) recruitment to human rheumatoid synovium in vivo. Human rheumatoid synovium and cartilage from five rheumatoid arthritis patients, obtained after joint replacement surgery, were engrafted subcutaneously to 6-8-week-old SCID CB17 mice. Synovial tissues were injected with recombinant human IL-4 (rhIL-4, 100 ng; rhIL-10, 100 ng), both cytokines, or tumour necrosis factor-alpha (TNF-alpha) (1000 U), or phosphate-buffered saline twice a week for 4 weeks. The graft was removed and immunochemical analysis was carried out to assess intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin expression. Moreover, cartilage degradation was assessed through the quantification of the erosion surface on a computerized image of the engrafted cartilage at high power view. MNC recruitment in the synovial tissue was determined by labelling blood MNC with indium-111 before their intraperitoneal injection. The activity obtained in the region of the graft were determined with a gamma camera 72 hr postinjection. The results are expressed as a percentage of initial injected activity. After 4 weeks we observed a decrease of cartilage area in controls (77 +/- 8%), inhibited after injection of IL-4, IL-10, or both cytokines (90 +/- 3%, 89.1 +/- 4%, 89.2 +/- 5% respectively), and 57 +/- 17% after TNF-alpha injection. The % MNC activity in the graft decreased to 77 +/- 81% (NS), 9 +/- 4% (P < 0.003) and 19 +/- 6% (P < 0.007) compared with untreated synovial tissue after treatment with IL-4, IL-10, or both cytokines, respectively. Moreover, IL-10 but not IL-4 decreased the expression of ICAM-1 but not VCAM-1 or E-selectin by synovial cells. These results suggest that IL-10 and IL-4 could have chondroprotective properties, and that IL-10 but not IL-4 inhibits MNC traffic towards the synovial tissue efficiently.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jorgensen</LastName><ForeName>C</ForeName><Initials>C</Initials><Affiliation>Service d'Immuno-Rhumatologie, Lapeyronie Hospital, Montpellier, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Apparailly</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Couret</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Canovas</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Jacquet</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sany</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>ENGLAND</Country><MedlineTA>Immunology</MedlineTA><NlmUniqueID>0374672</NlmUniqueID><ISSNLinking>0019-2805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Cell Adhesion Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance>Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance>Interleukin-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1988 Mar;31(3):315-24</RefSource><PMID Version="1">3358796</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunology. 1997 Aug;91(4):565-71</RefSource><PMID Version="1">9378496</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1991 Nov 1;174(5):1209-20</RefSource><PMID Version="1">1940799</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1991 Dec 15;147(12):4167-71</RefSource><PMID Version="1">1684374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1992 May 1;89(9):4076-80</RefSource><PMID Version="1">1533284</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1993 Feb;36(2):137-46</RefSource><PMID Version="1">7679271</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1993 Feb;36(2):147-57</RefSource><PMID Version="1">8431203</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1993 Aug 15;151(4):2105-15</RefSource><PMID Version="1">8345197</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1993 Dec 15;151(12):7324-36</RefSource><PMID Version="1">8258726</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Rheumatol. 1994 Jan;21(1):10-6</RefSource><PMID Version="1">8151561</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1994 May 1;179(5):1517-27</RefSource><PMID Version="1">8163935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8562-6</RefSource><PMID Version="1">8078923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1994 Nov;37(11):1664-71</RefSource><PMID Version="1">7526870</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1995 Jan;95(1):264-71</RefSource><PMID Version="1">7529260</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1995 Mar 1;181(3):1197-203</RefSource><PMID Version="1">7532681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1995 Jul;38(7):946-52</RefSource><PMID Version="1">7612044</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1995 Nov;96(5):2304-10</RefSource><PMID Version="1">7593617</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Rev. 1995 Apr;144:195-223</RefSource><PMID Version="1">7590814</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 1995 Oct;54(10):836-40</RefSource><PMID Version="1">7492224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Rheumatol. 1995 Nov;22(11):2020-6</RefSource><PMID Version="1">8596138</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncol Res. 1995;7(3-4):157-63</RefSource><PMID Version="1">8555649</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1996 Mar;39(3):386-95</RefSource><PMID Version="1">8607887</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1996 Mar;39(3):495-503</RefSource><PMID Version="1">8607899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1996 May;39(5):829-35</RefSource><PMID Version="1">8639180</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1996 Mar 15;156(6):2316-23</RefSource><PMID Version="1">8690923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Exp Immunol. 1996 Oct;106(1):20-5</RefSource><PMID Version="1">8870693</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1996 Dec;39(12):1961-9</RefSource><PMID Version="1">8961900</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 1997 Feb;40(2):249-60</RefSource><PMID Version="1">9041936</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1997 Apr 1;158(7):3492-8</RefSource><PMID Version="1">9120311</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Exp Immunol. 1988 Sep;73(3):449-55</RefSource><PMID Version="1">3264773</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cartilage, Articular</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Adhesion Molecules</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, SCID</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Synovial Membrane</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Transplantation, Heterologous</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1364130</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9659224</ArticleId><ArticleId IdType="pmc">PMC1364130</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E53 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003E53 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9659224
|texte= Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9659224" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |